glp-1 options for type 2 diabetes and obesity 2025 Orforglipron, approved as Foundayo on April 1, 2026, adds another oral option chronic weight management in adults with or overweight plus at least one weight-related condition. The clinical relevance GLP-1 Impact: How GLP-1s Are

Moreover, the coexistence of NAFLD and type 2 diabetes leads to a worse metabolic profile and higher cardiovascular risk [6, 7]

Hes used these supplements to reenergize hundreds of patients for long time

Mayo Clinic announced 18 AI HealthTech startups for cohort 7 of its Platform Accelerate program, bringing the total to 76 AI startups since 2022

Thats a care failure, not a drug failure

INTRODUCTION The recent and rapid rise of the GLP-1 receptor agonists semaglutide (Ozempic, Rybelsus and Wegovy) and tirzepatide (Mounjaro and Zepbound) offers a critical lens through which we can examine the intersection of financialization, patent abuse, and health inequities in the pharmaceutical industry

Wu, G., Fang, YZ, Yang, S., Lupton, JR, & Turner, ND (2004)